GlassScriptPhysician profile
Cameron L Nelson
NPI 1932488053
$2,796.82
in general payments reported to CMS, 2019-2025
14 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.73 · 2022: $224 · 2023: $238 · 2024: $456 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278 · Travel and Lodging: $1,172 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.40 |
| Travel and Lodging | $1,172.30 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,817.13 | 2023-2025 | Inspire |
| Abbvie INC. | $370.52 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $134.53 | 2024-2025 | |
| Novo Nordisk INC | $108.34 | 2022-2025 | Ozempic, Rybelsus |
| Saluda Medical Americas, INC. | $90.59 | 2024 | Evoke |
| Harmony Biosciences LLC | $71.83 | 2024-2025 | |
| Lilly USA, LLC | $37.72 | 2023-2025 | Zepbound, Emgality, Reyvow |
| Dexcom, INC. | $36.27 | 2022 | |
| Axsome Therapeutics, INC. | $32.95 | 2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $24.62 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.35 | 2025 | Caplyta |
| Boston Scientific Corporation | $21.48 | 2022 | |
| Pfizer INC. | $13.77 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.